News

Are you ready to advocate for the bleeding disorders community? Join us at Washington Days 2025 for a powerful and impactful experience. Learn…

The T.H.R.I.V.E. campaign is an initiative to educate individuals with bleeding disorders and their support networks about six key steps for leading…

Bone health isn’t necessarily top of mind — especially at younger ages — but it should be. One study revealed that people with…

Chronic pain affects up to 58% of people with hemophilia, impacting mobility, mental health and daily activities. Recognizing this widespread issue, the…

The National Bleeding Disorders Foundation (NBDF) has announced that three new documents have been issued by the Medical and Scientific Advisory Council…

For thirty years, the Coalition for Hemophilia B has improved the quality of life for people with hemophilia B and their families…

A new study sheds light on the challenges of diagnosing and managing gastrointestinal (GI) bleeding in individuals with severe von Willebrand disease…

CHOP Researchers Investigate Durability of Hemophilia A Gene Therapy Findings of a new preclinical study published online in Nature Communications may help address lingering…

On October 11, 2024, Pfizer announced that the U.S. FDA approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency…

 new preclinical study led by CHOP researchers, published in Nature Communications, offers promising insights into the long-term effectiveness of hemophilia A gene therapy….

The World Federation of Hemophilia (WFH) announced the 2025 World Hemophilia Day theme: Access for All: Women and Girls Bleed Too. Learn…

Phil Gattone said, “We greatly appreciate Pfizer’s innovative efforts in developing this novel treatment option that addresses some of the ongoing challenges…

Dive into NBDF’s August 2024 Government Relations Update for essential information on Medicaid unwinding, ACA premium tax credits, NIH reform, and state-level…

A manufacturing deviation at NovoNordisk’s Danish facility has led to potential underfilling of vials for NovoSeven©, NovoEight©, and Esperoct© – crucial treatments…

A session on von Willebrand Disease (VWD) at the National Bleeding Disorders Foundation Conference this past summer, highlighted patient-driven treatment advancements and…

A comprehensive document identifies 50 various publications about gene therapy, much of it accessible for parents and patients. The list includes: FAQs,…

Multimillion-dollar gene therapies were long awaited and desired, but patients were unsure whether insurance would cover the costs. So far, very few patients are…

These new medical-based webinars will speak to key topics relevant to the care of patients with inherited bleeding disorders. NBDF is excited…

Learn about Gene Therapy for Hemophilia with NBDF’s new resource collection. Find answers, research, and support. The National Bleeding Disorders Foundation (NBDF) is…

The National Bleeding Disorders Foundation (NBDF) is pleased to announce a new enduring and accredited educational activity available to healthcare providers. “Exploring…

BioMarin recently announced that they will be changing the scope of their efforts to manufacture and market their gene therapy product ROCTAVIAN.™…

by: Patricia Inácio, PhD | July 9, 2024 Hemgenix, the first approved hemophilia B gene therapy, was administered to two patients in France, marking the first time…

Gene therapy is a welcome treatment for patients, which has been anticipated for decades. But how do parents and patients discuss this…

NBDF’s National Youth Leadership Institute (NYLI) provides 18-24 year olds in the bleeding disorders community with leadership opportunities to encourage personal growth,…